| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/06/2011 | US20110002850 Nitro-Imidazole Hypoxia Imaging Agent |
| 01/06/2011 | US20110002845 Methods of treating, diagnosing or detecting fgf21-associated disorders |
| 01/06/2011 | US20110002844 Stabilization of macromolecular membranes |
| 01/06/2011 | US20110000480 Administration of interferon for prophylaxis against or treatment of pathogenic infection |
| 01/06/2011 | CA2804190A1 Phosphorus containing quinazoline compounds and methods of use |
| 01/06/2011 | CA2803987A1 Non-sedating antihistamine injection formulations and methods of use thereof |
| 01/06/2011 | CA2770153A1 Improved formulations for nonsurgical exogenous crosslink therapy |
| 01/06/2011 | CA2769627A1 Antimicrobial/preservative compositions comprising botanicals |
| 01/06/2011 | CA2767183A1 Covalent inhibition of bacterial quorum sensing |
| 01/06/2011 | CA2767130A1 Fluorinated derivatives of 3-hydroxypyridin-4-ones |
| 01/06/2011 | CA2767129A1 Compositions and methods for silencing apolipoprotein b |
| 01/06/2011 | CA2767127A1 Novel lipid formulations for delivery of therapeutic agents to solid tumors |
| 01/06/2011 | CA2767097A1 Pyrazolopyrimidine jak inhibitor compounds and methods |
| 01/06/2011 | CA2767096A1 Pyrazole derivatives, preparation thereof, and therapeutic use thereof |
| 01/06/2011 | CA2767064A1 Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors |
| 01/06/2011 | CA2767051A1 Novel 2,3-dihydro-1h-imidazo(1,2-a)pyrimidin-5-one derivatives, preparation thereof, and pharmaceutical use thereof |
| 01/06/2011 | CA2767029A1 A method of treatment of a neurological disorder |
| 01/06/2011 | CA2766972A1 Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor |
| 01/06/2011 | CA2766967A1 Imidazo [4,5-c]quinoline derivatives and their use in the treatment of tumors and/or inflammation |
| 01/06/2011 | CA2766909A1 Novel 1,2,3,4-tetrahydro-pyrimido(1,2-a)pyrimidin-6-one derivatives, preparation thereof, and pharmaceutical use thereof |
| 01/06/2011 | CA2766884A1 Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application |
| 01/06/2011 | CA2766882A1 Therapeutic compounds and compositions |
| 01/06/2011 | CA2766873A1 Therapeutic compositions and related methods of use |
| 01/06/2011 | CA2766855A1 Substituted 2-carboxamide cycloamino ureas |
| 01/06/2011 | CA2766853A1 2-carboxamide cycloamino ureas useful as pi3k inhibitors |
| 01/06/2011 | CA2766834A1 Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders |
| 01/06/2011 | CA2766762A1 Novel conjugates, preparation thereof, and therapeutic use thereof |
| 01/06/2011 | CA2766706A1 L-serine to be used as a drug for preventing and/or treating an inflammatory response of the skin |
| 01/06/2011 | CA2766388A1 Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof |
| 01/06/2011 | CA2766269A1 Method for improving bioavailability of latanoprost |
| 01/06/2011 | CA2766239A1 Medicinal carbohydrates for treatment of respiratory conditions |
| 01/06/2011 | CA2766202A1 Pharmaceutical tablet containing a liquid filled capsule |
| 01/06/2011 | CA2766178A1 Combretastatins for prevention of posterior capsule opacification |
| 01/06/2011 | CA2766139A1 Substituted 4-hydroxypyrimidine-5-carboxamides |
| 01/06/2011 | CA2766082A1 Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy |
| 01/06/2011 | CA2766073A1 Alkoxy-carbonyl-amino-alkynyl-adenosine compounds and derivatives thereof as a2ar agonists |
| 01/06/2011 | CA2766067A1 3-cyanoquinoline tablet formulations and uses thereof |
| 01/06/2011 | CA2766056A1 Substituted 4-hydroxypyrimidine-5-carboxamides |
| 01/06/2011 | CA2765932A1 Use of interfering rna for treating an hiv infection |
| 01/06/2011 | CA2765852A1 Compositions comprising finafloxacin and methods for treating ophthalmic, otic, or nasal infections |
| 01/06/2011 | CA2765836A1 Phenylethanoic acid, phenylpropanoic acid and phenylpropenoic acid conjugates and prodrugs of hydrocodone, methods of making and use thereof |
| 01/06/2011 | CA2765475A1 2-carboxamide-7-piperazinyl-benzofuran derivatives 774 |
| 01/06/2011 | CA2764878A1 Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents |
| 01/06/2011 | CA2764425A1 Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid |
| 01/06/2011 | CA2764193A1 Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics |
| 01/06/2011 | CA2764185A1 Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics |
| 01/06/2011 | CA2763692A1 Neurotoxins exhibiting shortened biological activity |
| 01/06/2011 | CA2763194A1 Treatment and prevention of dengue virus infections |
| 01/06/2011 | CA2753290A1 Topical skin treatment kits |
| 01/05/2011 | EP2270894A1 Use of organic mesomeric compounds as dotands |
| 01/05/2011 | EP2270511A2 Method of therapy |
| 01/05/2011 | EP2270505A1 A method of screening a cell death inhibitor using macrophage migration inhibitory factor (MIF) |
| 01/05/2011 | EP2270503A2 Method for diagnosing non-small cell lung cancers |
| 01/05/2011 | EP2270237A2 Method for manufacturing arabinoxylan |
| 01/05/2011 | EP2270230A2 Antisense modulation of insulin-like growth factor binding protein 5 expression |
| 01/05/2011 | EP2270191A1 Preparation of microbial oil containing polyunsaturated fatty acids |
| 01/05/2011 | EP2270182A2 DSRNA as insect control agent |
| 01/05/2011 | EP2270181A2 DSRNA as insect control agent |
| 01/05/2011 | EP2270162A2 Conserved HBV and HCV sequences useful for gene silencing |
| 01/05/2011 | EP2270107A1 Compounds for Dual Photodiagnosis and Therapy |
| 01/05/2011 | EP2270053A1 Humanized AXL antibodies |
| 01/05/2011 | EP2270052A2 Antibodies to OPGL |
| 01/05/2011 | EP2270050A1 Anti-CD19 antibodies with reduced immunogenicity |
| 01/05/2011 | EP2270043A1 Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor |
| 01/05/2011 | EP2270023A1 New polymorphic form of 5-azacytidine |
| 01/05/2011 | EP2270022A1 New polymorphic form of 5-azacytidine |
| 01/05/2011 | EP2270018A1 Antitumoral analogs |
| 01/05/2011 | EP2270014A1 Azepine inhibitors of janus kinases |
| 01/05/2011 | EP2270011A1 Condensed imidazolo derivatives for the inhibition of aromatase |
| 01/05/2011 | EP2270010A1 11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepins |
| 01/05/2011 | EP2270008A1 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinases inhibitors |
| 01/05/2011 | EP2270007A1 2-N-{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate |
| 01/05/2011 | EP2270006A1 Pyridazine derivatives useful as vanilloid receptor ligands |
| 01/05/2011 | EP2270005A1 Prodrug of an ice inhibitor |
| 01/05/2011 | EP2270004A1 Caspase inhibitors and uses thereof |
| 01/05/2011 | EP2270002A1 Quinazoline derivatives as histamine H4-receptor inhibitors for use in the treatment of inflammatory disorders |
| 01/05/2011 | EP2270000A1 Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts |
| 01/05/2011 | EP2269999A1 Method for preparing crystalline s-omeprazole strontium hydrate |
| 01/05/2011 | EP2269996A1 Medicinal composition containing benzo[a]phenoxanthin compound as the active ingredient for preventing or treating protozoal disease |
| 01/05/2011 | EP2269994A1 The polymorphs of 4-anilinoquinazoline derivatives, the preparation methods and uses thereof |
| 01/05/2011 | EP2269993A1 2-aminoquinazoline derivative |
| 01/05/2011 | EP2269992A1 Bicyclic pyrimidinones for the treatment of viral infections |
| 01/05/2011 | EP2269991A2 Substituted tetracycline compounds |
| 01/05/2011 | EP2269990A1 Heterocyclic compound |
| 01/05/2011 | EP2269989A1 Iminopyridine derivative and use thereof |
| 01/05/2011 | EP2269988A2 Anthranilic acid amides and pharmaceutical use thereof |
| 01/05/2011 | EP2269985A2 Substituted tetracycline compounds |
| 01/05/2011 | EP2269980A1 Creatine amides, a method for the production thereof and an agent exhibiting a neuroprotective action |
| 01/05/2011 | EP2269978A2 Substituted tetracycline compounds |
| 01/05/2011 | EP2269977A2 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
| 01/05/2011 | EP2269972A1 Oviedomycin derivatives, method for obtaining same and use thereof |
| 01/05/2011 | EP2269694A2 Antituberculous composition comprising oxazole compounds |
| 01/05/2011 | EP2269654A2 Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
| 01/05/2011 | EP2269653A1 Composition for stabilizing -blocker, and transdermally absorbable preparation comprising the composition |
| 01/05/2011 | EP2269651A2 Stabilisation of macrolides |
| 01/05/2011 | EP2269650A2 Carrier for enteral administration |
| 01/05/2011 | EP2269648A2 Pharmaceutical compositions based on anticholinergically effective compounds and beta-mimetics |
| 01/05/2011 | EP2269647A2 Pharmaceutical compositions based on anticholinergically effective compounds and beta-mimetics |
| 01/05/2011 | EP2269645A2 Topical aminolevulinic acid-photodynamic therapy for acne vulgaris |
| 01/05/2011 | EP2269630A1 Novel anti-nematode therapies targetting STRM-1 |